ILD Community Network: Linking APPs with ILD Experts



Our Alliance

Mission of the ILD Community Network
To unite, empower, and support individuals and organizations in advancing awareness, research, and care for those impacted by Interstitial Lung Disease.

Connect to ILD experts in your region
Partner with trusted ILD experts in your region to unlock your potential and achieve your goals.
ILD EXPERTS


Jeanette Hart
PA-C
Jeannette Hart is a board-certified physician assistant with over 13 years of experience specializing in rheumatology. She earned her Master of Clinical Health Services (MCHS) through the University of Washington’s MEDEX Physician Assistant Program in 2012. She began her career in private practice and successfully navigated transitions through both a hospital acquisition and a merger with a large healthcare system—all while refining her clinical expertise and leading efforts to improve patient access, operational efficiency, and best practices in rheumatology care. Committed to advancing healthcare delivery, Jeannette pursued a second master’s degree in Health Administration (MHA), further strengthening her leadership in clinical operations. She is now co-founder and co-owner of PNW Arthritis and Rheumatology, a private rheumatology practice opening October 1, 2025. Jeannette is passionate about education and mentorship, regularly precepting PA students and family medicine residents in her community. She is also the Pacific Northwest Director for RhAPP (Rheumatology Advanced Practice Providers) and has proudly served on its faculty since its inception.


Amanda Mixon
PA-C
Amanda Mixon, PA-C, is a physician assistant specializing in rheumatology at UCHealth's Rheumatology Clinic in Fort Collins, Colorado. With over 17 years of experience, she focuses on managing inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and connective tissue diseases like lupus. Amanda emphasizes a team-based approach to care, working closely with both patients and specialists to ensure timely and effective treatment plans. She is also a co-founder of the Rheumatology Advanced Practice Providers (RhAPP) group, where she contributes to educating and supporting colleagues in rheumatology. Amanda's dedication to patient care extends to fostering collaboration between rheumatology and dermatology, particularly in managing complex connective tissue diseases that involve both skin and joint manifestations


William Saalfeld
DNP
William Saalfeld is an Adult-Gerontology Acute Care Nurse Practitioner specializing in Rheumatology at the Arthritis Center of Nebraska, where he has practiced since 2017. He holds a Doctor of Nursing Practice from the University of Nebraska Medical Center. Before specializing in rheumatology, he gained experience as a registered nurse in critical care and palliative care. Saalfeld is a member of the Association of Rheumatology Health Professionals.


Candace Ryan
PA-C
Candace Ryan attended the University of Southern Mississippi where she earned a bachelor's degree in Biologic. After relocating to Arizona, she attended Midwestern University and received a master’s in physician assistant studies. She initially worked in Pediatrics and then transitioned to Rheumatology where she has been for the past 17 years at the Arizona Arthritis and Rheumatology Associates. Candace has been on faculty with RhAPP for the past 4 years. In her spare time, she enjoys spending time with her family, riding her bike, and playing with her dogs.


Shayla Sanders
FNP-BC
Shayla Sanders is a board-certified Family Nurse Practitioner with extensive experience in providing comprehensive care to patients with complex medical conditions. Passionate about patient education and evidence-based practice, Shayla focuses on empowering individuals through personalized care plans. With a strong background in [specific specialty or focus area, if known], she is dedicated to fostering collaborative patient-provider relationships to optimize health outcomes.


Heather Mambretti
PA-C
Heather Mambretti, PA-C, is a physician assistant specializing in rheumatology at Texas Rheumatology in League City, Texas. She has been practicing since 2011 and provides care for patients with autoimmune and musculoskeletal conditions. Heather is affiliated with Texas Rheumatology and works alongside other specialists to offer comprehensive treatment plans for her patients. She is dedicated to improving the health and well-being of individuals dealing with rheumatologic diseases.


Heather Finlayson
PA-C
Heather Finlayson, MS, PA-C, is a certified Physician Assistant for Summit Rheumatology in Littleton, Colorado. She previously worked at National Jewish Health Rheumatology and started at Colorado Arthritis Associates in Rheumatology in 2012. She has also taught rheumatology courses at Rocky Vista University PA program since 2022. Heather is a member of the Association of Rheumatology Professionals (ARP) (division of American College of Rheumatology-ACR), and the Association of Women in Rheumatology (AWIR). She is currently the AWIR Denver Local Chapter Co-Lead, a Rheumatology Advanced Practice Providers (RhAPP) faculty member and has served on several ACR/ARP committees.


Shannon Ghizzoni
PA-C
Shannon Ghizzoni is a board-certified Physician Assistant specializing in rheumatology. With a passion for providing comprehensive care to patients with rheumatic conditions, Shannon focuses on patient education, disease management, and improving quality of life. She is dedicated to staying current with the latest advancements in rheumatology and fostering collaborative relationships with patients and healthcare teams to deliver personalized, evidence-based care.


Iris Zink
MSN, ANP, RN-BC
Iris Zink, MSN, ANP-BC, APRN, is a board-certified nurse practitioner specializing in rheumatology in East Lansing, Michigan. She co-founded Pine Hollow Partners, an Early Arthritis Intervention Clinic, in August 2016 to serve the underserved community. With over 24 years of experience, Iris is affiliated with McLaren Greater Lansing and Hayes Green Beach Memorial Hospital. She is dedicated to providing comprehensive care to patients with rheumatologic conditions, emphasizing early intervention to prevent deformity, disability, and death.


Naomi Amudala
RN, MSN
After graduating from MGH Institute of Health Professions in 2009 with a Master’s in Nursing, Naomi joined the division of Rheumatology at Boston University. Her primary focus was evaluating and managing patients with vasculitis as well as acting as co-investigator in multiple clinical trials in vasculitis. In 2018 she moved to Philadelphia and started working at Penn Medicine Rheumatology. The majority of her time continues to be dedicated to the clinical care of patients with vasculitis and other rare diseases as well as engaging in research. In 2022 Naomi joined the board of directors for RhAPP, which is a national organization for APPs and pharmacists in Rheumatology.


Kyle George
PA-C
Kyle George, PA-C, is a physician assistant with over 16 years of experience in rheumatology. He specializes in managing autoimmune diseases such as rheumatoid arthritis and osteoporosis. Kyle collaborates with a multidisciplinary team, providing personalized and comprehensive care to his patients.

Jessica Glennie
MSN, APRN
Jessica Glennie is a certified nurse practitioner who has worked in outpatient pulmonary medicine at the Cleveland Clinic in Cleveland, Ohio for 8 years. She manages patients in the interstitial lung disease program, including care of patients with idiopathic pulmonary fibrosis, autoimmune related interstitial lung disease, hypersensitivity pneumonitis, occupational lung diseases, and drug-induced interstitial lung disease. She is co-director of the Cleveland Clinic’s ILD multidisciplinary conference.

Jenny Williams
PA-C
Jenny Williams is Clinical Instructor of Medicine-Pulmonary Sciences & Critical Care at the University of Colorado Denver - Anschutz Medical Campus. She completed her medical training as a Physician Assistant at DeSales University. Since then, she has worked as a PA in General Pulmonary at St. Luke’s University Hospital in Pennsylvania, Lung Transplant and Cystic Fibrosis at Stanford University Hospital, and currently Interstitial Lung Disease and Lung Transplant at the University of Colorado.

Cori Fratelli
MSN, FNP-C
Cori Fratelli has a unique background in both basic science and clinical research, which has informed her interest in clinical medicine. Her past basic science research includes asthma, airway hyperresponsiveness, cystic fibrosis, and lung cancer. Her past clinical research includes COPD and interstitial lung disease (ILD). Presently, she is interested in how research translates into personalized medicine. Her clinical focus is mainly on ILD, but she also sees general pulmonary medicine patients, as needed.

Kelsey Cramer
MSN, AGACNP-BC, DNP
Kelsey Cramer is a board-certified adult-gerontology acute care nurse practitioner specializing in pulmonary medicine at Froedtert & the Medical College of Wisconsin. She focuses on interstitial lung disease (ILD), pulmonary hypertension (PH), and sarcoidosis. Kelsey earned her MSN and DNP from Rush University and is dedicated to delivering patient-centered care, education, and support for those managing complex lung conditions.

Kathy Lindell
PhD, RN, ATSF, FAAN
Kathleen Lindell is a nurse scientist and educator specializing in pulmonary fibrosis. She is an associate professor at the Medical University of South Carolina (MUSC) College of Nursing. Dr. Lindell is dedicated to advancing pulmonary care through research, education, and interdisciplinary collaboration, focusing on improving outcomes and quality of life for patients with pulmonary diseases.

Rebekah Edwards
DNP, FNP-C
Rebekah Edwards graduated with her NSM summa cum laude and earned her DNP from from the edson college of Nursing & Health Innovation. She currently works as a nurse practitioner in the advanced lung disease program at norton Thoracic Institute, Saint Joseph;s Hospital and Medical Center in Phoenix Arizona.

Felicia Mackey
MSN, FNP-BC, PCCN, CCRN
Felicia Mackey, MSN, FNP-BC, RN, PCCN, CCRN, is a board-certified Family Nurse Practitioner specializing in pulmonary and sleep medicine at Pulmonary Medicine Associates in Sacramento, California. She earned her Master of Science in Nursing with a Family Nurse Practitioner focus from Sonoma State University, following a Bachelor of Science in Nursing from California State University, Sacramento. Her foundational nursing education includes an Associate Degree in Nursing from Sacramento City College. Felicia holds multiple certifications, including Progressive Care Certified Nurse and Critical Care Registered Nurse, and is a member of the California Association of Nurse Practitioners and the American Association of Critical-Care Nurses. She is dedicated to partnering with patients to achieve their health goals, aiming for long, healthy, and happy lives.

Kelley Brant
NP
With over 17 years of diverse clinical experience, Kelley Brant is a dedicated healthcare professional with a passion for advancing pulmonary care. A graduate of San Diego State University with a BSN, Kelley began her career as a registered nurse in high-acuity settings, including the emergency room, ICU, and urgent care, where she honed her ability to excel in fast-paced, multidisciplinary environments. Kelley earned her MSN from the University of South Alabama and is double board-certified as a Family Nurse Practitioner and Emergency Nurse Practitioner. For the past 2.5 years, Kelley has served as a nurse practitioner specializing in pulmonary medicine, with a particular focus in interstitial lung disease (ILD). As an ILD program coordinator, Kelley has gained experience in managing complex patient populations and remains actively involved in general pulmonary care, including COPD, asthma, and other respiratory conditions. Kelley also has a strong interest in research, supporting her facility’s participation in several randomized controlled trials to advance evidence-based practice. Beyond clinical work, Kelley is committed to fostering connections within the healthcare community. As a member of AANP, CHEST, and Utah Nurse Practitioners, she emphasizes professional development and collaboration to improve patient outcomes and advance the field of pulmonary care.

Shannon Benesh
DNP, NP-C
Shannon Benesh, DNP, RN-BC, AGNP-C, is a Nurse Practitioner at Columbia University Irving Medical Center, specializing in Interstitial Lung Disease within the Division of Pulmonary and Critical Care. She earned her BSN from James Madison University and her MSN from Adelphi University, later completing her Doctor of Nursing Practice at Stony Brook University with a project focused on early advance care planning in ILD. Shannon has clinical experience as an RN at leading academic hospitals across various specialties and is certified as a Progressive Care Certified Nurse and Adult-Gerontology Nurse Practitioner. She is an active member of AANP, has contributed to published ILD research, and participates in national advisory boards dedicated to improving ILD care. She lives in Brooklyn with her husband and their dog and enjoys traveling, reading, running, and the occasional cocktail.
ILD Community Network Educational Events

CME EVENT
6th Annual RhAPP National Conference
September 25 @ 12:00 pm - September 27 @ 12:00 pm MST
Course Overview: Rheumatology Advanced Practice Providers (RhAPP) is an initiative dedicated to developing educational programs, providing professi..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
October 02 @ 06:00 pm - 08:00 pm CST
Register Today!..

CME EVENT
APAPP Regional Conference
September 30 @ 05:00 pm - 08:30 pm EST
Please register to join us at the Hilton Cleveland Downtown on September 30, 2025, at 5:00 PM EST for the APAPP Regional Meeting. ..

CME EVENT
APAPP Regional Conference
October 07 @ 05:00 pm - 08:30 pm MST
Please register to join us at the Hilton Garden Inn Denver/Cherry Creek on October 7, 2025, at 5:00 PM MST for the APAPP Regional Meeting. ..

CME EVENT
RhAPP Regional Chapter Summit
October 16 @ 05:00 pm - 08:30 pm EDT
Register Now!..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
November 04 @ 06:00 pm - 08:00 pm EST
Register Today!..

CME EVENT
APAPP Regional Conference
October 14 @ 05:00 pm - 08:30 pm CST
Please register to join us at the Marriott Dallas Las Colinas on October 14, 2025, at 5:00 PM CST for the APAPP Regional Meeting. ..

CME EVENT
APAPP Regional Conference
November 05 @ 05:00 pm - 08:30 pm EST
Details Coming Soon!..

CME EVENT
APAPP Regional Conference
November 12 @ 05:00 pm - 08:30 pm EST
Details Coming Soon!..

CME EVENT
APAPP Regional Conference
November 13 @ 05:00 pm - 08:30 pm PST
Register to join us in Los Angeles for the APAPP Regional Conference. More details coming soon!..

CME EVENT
RhAPP Regional Chapter Summit
November 15 @ 09:00 am - 12:30 pm EDT
Register Now!..

CME EVENT
RhAPP Regional Chapter Summit
December 06 @ 09:00 am - 12:30 pm EDT
Registration Details Coming Soon!..

CME EVENT
RhAPP Regional Chapter Summit
November 06 @ 05:00 pm - 08:30 pm CDT
Register Now!..

CME EVENT
RhAPP Regional Chapter Summit
January 16 @ 05:00 pm - 08:00 pm PST
Details Coming Soon!..

CME EVENT
RhAPP Regional Chapter Summit
October 30 @ 05:00 pm - 08:30 pm EST
Register Now!..

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
November 06 @ 05:30 pm - 08:00 pm MST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
October 16 @ 06:00 pm - 08:30 pm MST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
October 23 @ 05:30 pm - 08:30 pm EST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
October 09 @ 06:00 pm - 08:30 pm EST

Bridging Specialties: Tackling Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
November 25 @ 12:00 pm - 12:00 pm EST
ILD Digital Learning Center
Podcasts
Podcasts


Rheumatology in the Lungs
July 2025
24:47 m
How can Advanced Practice Providers (APPs) in rheumatology and pulmonology collaborate more effectively to manage interstitial lung disease (ILD) and connective tissue diseases (CTDs)? In this engaging episode of the APAPP Broadcast, recorded live at the Second Annual National APAPP Conference in Nashville, experts Jessica Glennie, PA-C (Cleveland Clinic), Amanda Mixon, PA-C (Colorado), and Cori Fratelli, NP (National Jewish Health) explore clinical overlaps between autoimmune rheumatic diseases and lung involvement, such as ILD in rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren’s syndrome, and myositis. The panel shares clinical pearls on: -How to recognize signs of CTDs in pulmonary patients -The importance of labs and imaging in early diagnosis -What rheumatology APPs should ask about pulmonary symptoms -The power of cross-specialty collaboration -Real-world case insights, including navigating bird-related hypersensitivity pneumonitis


Immunology of the Lung Podcast
July 2025
11:40 m
Tune in from the Annual APAPP National Conference for a dynamic episode of the APAPP Podcast featuring Corinne Young, FNP-C, Amanda Michaud, PA-C, and Brian Bizik, PA-C—three expert APPs leading engaging sessions on lung immunology, rare immune deficiencies, and COPD updates. Amanda breaks down the “Immunology of the Lung 101” and her “Finding the Zebras” series, where she highlights key red flags for primary immune deficiencies, sharing real patient cases and diagnostic tips to help clinicians recognize and manage these commonly missed conditions. Brian shares practical takeaways from the latest GOLD COPD guidelines, including how biomarkers like eosinophil counts can guide personalized inhaled corticosteroid decisions. Whether you're managing patients with asthma, COPD, or unexplained recurrent infections, this episode delivers clinical pearls you can apply in your practice right away. Discover why this APP-led meeting stands out as a must-attend event for pulmonary and immunology providers. Be sure to like, subscribe, and follow us for more expert-driven conversations.


ILD 101, ILD 102, ILD Peds
July 2025
20:57 m
Join Jessica Glennie, APRN, Naomi Miyazawa, PA-C, and Cori Fratelli, FNP, from the 2025 APAPP National Conference as they explore pediatric and adult interstitial lung disease (ILD). This episode covers diagnosis, disease progression, anti-inflammatory and anti-fibrotic therapies, and the importance of multidisciplinary care. Learn about pediatric ILD (CHILD), autoimmune-related ILD, and new treatment guidelines—all through real-world clinical insights.


Advancing ILD & PH-ILD Care
July 2025
21:35 m
Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.


Practical Considerations for Screening for PH in ILD Clinics
July 2025
17:17 m
In this insightful Podcast, expert advanced practice providers, Corinne Young & Jessica Glennie share practical strategies for identifying and screening for pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). They discuss how to recognize subtle red flags—such as declining DLCO, changes in walk test performance, and discrepancies in pulmonary function test results—that may indicate the presence of PH. The conversation also covers when to order echocardiograms, when to refer for right heart catheterization, and how to distinguish ILD progression from the development of PH. With a focus on multidisciplinary collaboration and real-world clinical workflows, this episode offers valuable, actionable guidance for APPs, pulmonologists, and care teams managing ILD populations.


Understanding MAC with Jennifer Faber- Gerling
December 2024
30:30 m
In this episode, Corinne Young interviews Jennifer Faber- Gerling about mycobacterium avian complex (MAC). They discuss the bacterium itself, the rise in cases, screening and diagnosis, treatment and side effects, reinfection versus reactivation, and symptom management. Jennifer emphasized the importance of close surveillance, collaboration with a multidisciplinary team, and individualized care for patients with MAC.


Idiopathic Shortness of Breath part 2 Dysfunctional Breathing Clinic
December 2024
29:41 m
Nurse practitioner Cori Fratelli from National Jewish Health discusses breathing pattern disorders, related to unexplained dyspnea. Cori advocates to consider these disorders, discusses treatment methods like breath retraining, inspiratory muscle training, and emphasizes the need for more research and specialized clinics.
Webcast
Webcast


What Pulmonology APPs Can Do After an ILD Diagnosis to Support a Rheumatology Workup
July 2025
01:42 m
Once you've confirmed a diagnosis of interstitial lung disease (ILD), what’s next? In this practical and fast-paced discussion, Amanda Mixon, PA-C, shares actionable steps for evaluating patients for underlying autoimmune or connective tissue diseases. Learn what symptoms to ask about—joint pain, morning stiffness, skin lesions, Raynaud’s, dry eyes or mouth—and how labs and rheumatology collaboration can support early detection and accurate diagnosis. This video offers clinical pearls for APPs working in pulmonology who want to strengthen their diagnostic acumen and build better cross-specialty communication with rheumatology colleagues. Topics covered: – What symptoms may signal underlying rheumatic disease in ILD patients – Key lab tests to guide your differential – When to refer to rheumatology – The value of real-time collaboration across specialties ILD care is better together. Watch now to improve your approach to autoimmune workups in pulmonary patients.


Scleroderma Treatment
July 2025
01:52 m
In this focused discussion, Amanda Mixon, PA-C shares a practical approach to managing patients with systemic sclerosis (Scleroderma), with an emphasis on individualized care based on disease manifestation. From echocardiograms to pulmonary imaging, medication choices to vascular complications, this talk provides key insights into how APPs can tailor care to improve outcomes. Learn how to approach limited vs. diffuse Scleroderma, when to avoid glucocorticoids, and how to manage complications like digital ulcers and pulmonary involvement. Key takeaways include: – When to use echocardiograms, CT scans, and other diagnostics – Medication strategies: Mycophenolate, Selenomab, CCBs, ARBs, and more – Avoiding glucocorticoids in diffuse disease and managing risk of renal crisis – Treating symptomatically: digital ulcers, skin fibrosis, and blood flow support This is a must-watch for APPs in rheumatology, pulmonology, or primary care managing patients with Scleroderma.


Systemic Sclerosis Presentation
July 2025
11:52 m
In this powerful and personal clinical reflection, Amanda Mixon, PA-C, shares her journey treating patients with diffuse systemic sclerosis (Scleroderma), including key lessons learned from working at a major Scleroderma center at Northwestern. From building trust with colleagues to managing life-threatening complications like Scleroderma Renal Crisis, this video offers invaluable insights for APPs and clinicians navigating this complex autoimmune disease. You’ll hear firsthand experiences treating patients with severe skin involvement, pulmonary fibrosis, digital ulcers, GI complications, and early vasculopathy. Learn why RNA polymerase III positivity is a red flag, how to differentiate diffuse from limited SSc, and why early diagnosis and treatment are essential. What you’ll learn: – What distinguishes diffuse Scleroderma from limited forms – Clinical signs to recognize early: Raynaud’s, skin tightening, telangiectasia – The dangers of steroid use and Scleroderma Renal Crisis – Why collaboration and early referral to SSc centers can save lives – Real stories and clinical pearls from treating high-risk patients This is a must-watch for any clinician managing autoimmune diseases—especially those treating interstitial lung disease, GI complications, or vasculitis related to Scleroderma.


Idiopathic Inflammatory Myopathies and Pulmonary Disorders Including ILD
July 2025
04:59 m
Inflammatory myopathies—like dermatomyositis, polymyositis, and inclusion body myositis—can be difficult to diagnose and manage, especially when they overlap with interstitial lung disease (ILD). In this clinical discussion, Amanda Mixon, PA-C, breaks down what to look for, from subtle signs like "mechanic's hands" to more serious red flags like MDA5-positive rapidly progressive ILD. Special attention is given to anti-synthetase syndrome, a condition often associated with ILD, arthritis, and elevated CK levels, and how antibody testing (e.g., Jo-1, SSA, MDA5) can guide diagnosis and urgency of care. You’ll also learn how to approach cancer screenings in patients with dermatomyositis and why a full malignancy workup is essential. What you'll learn: – How to identify anti-synthetase syndrome and inflammatory myopathies – Key clinical signs: weakness, mechanic’s hands, non-erosive arthritis – Understanding the myositis antibody panel and its clinical utility – The connection between dermatomyositis and malignancy risk – When and how to conduct a thorough cancer screening – Treatments including JAK inhibitors, IVIG, and rituximab Perfect for APPs, pulmonologists, and rheumatology teams, this video empowers you to catch early signs, personalize diagnostics, and take action.


Limited Cutaneous Scleroderma Presentation
July 2025
01:48 m
In this quick but focused clinical overview, Amanda Mixon, PA-C, explains how to identify and differentiate limited systemic sclerosis (also known as CREST syndrome) from diffuse scleroderma. Associated with centromere antibodies, limited scleroderma primarily affects the distal extremities and face, and while skin involvement is less severe, patients face distinct long-term risks—especially pulmonary hypertension. This video breaks down the classic CREST acronym (Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, and Telangiectasias), along with practical tips for early recognition and long-term management. What you'll learn: – How to recognize clinical features of limited scleroderma – The role of centromere antibodies vs. SCL-70 in diagnosis – Early signs like Raynaud’s and esophageal symptoms – What to monitor for in years 5–10: pulmonary hypertension, vascular disease – Differentiating CREST from diffuse disease This is an essential update for APPs and clinicians managing autoimmune connective tissue disease, especially in patients with progressive symptoms involving the skin, GI tract, and lungs.


Sjogren’s Disease and ILD
July 2025
01:43 m
In this concise and clinically insightful discussion, Amanda Mixon, PA-C, breaks down what to look for when suspecting Sjögren’s syndrome—an autoimmune condition marked by chronic dry eye and dry mouth, fatigue, and systemic manifestations. Often associated with SSA and SSB antibodies, Sjögren’s can overlap with interstitial lung disease (ILD), making it especially important for pulmonary and rheumatology providers to recognize early. Learn how to distinguish classic symptoms from environmental causes, when to consider antibody testing, and which patients may be at higher risk for more severe complications like ILD. What you’ll learn: – Clinical clues for identifying Sjögren’s in practice – Role of SSA and SSB antibodies in diagnosis – Recognizing extra-glandular manifestations: fatigue, arthritis, rashes – When to suspect ILD in Sjögren’s patients – Medication options and early steroid use considerations Whether you’re in primary care, pulmonology, or rheumatology, this video equips you to ask the right questions and understand the systemic risks behind what may appear to be “just dry mouth.”
Industry Resources

Identifying and Monitoring Autoimmune ILD | Insights in ILD

Pulmonary Function Tests (PFTs) Pocket Guide | Insights in ILD

HRCT Pocket Guide | Insights in ILD

History Taking Pocket Guide | Insights in ILD

Imaging Atlas of Interstitial Lung Diseases | Insights in ILD

Rad Rounds UIP to IPF Mobile Application
Rad Rounds - UIP to IPF is an innovative, peer-reviewed resource that provides practicing and future pulmonologists and radiologists with training and references for recognizing and evaluating usual interstitial pneumonia (UIP) and interstitial lung diseases (ILDs) on high resolution computed tomography (HRCT). Through this application the user can access learning materials such as a step-by-step pattern recognition algorithm, utilizing user-provided HRCT scans, an interactive UIP/ILD glossary and image gallery to further assist in the evaluative process, several “test your knowledge” quizzes, and a series of short informational videos, covering subjects such as: Basic HRCT Technique, Imaging Positions, and Recognizing Features of ILD on HRCT. This app is ideal for: radiologists that would like to use the interactive algorithm to help assess their HRCT scans, pulmonologists that want to evaluate their own cases or learn more about HRCT in the diagnosis of ILD, and medical students and residents that want to learn about HRCT and ILD. Download now and find out: Is It UIP? Available on the App Store: https://apps.apple.com/us/app/rad-rounds-uip-to-ipf/id1327938328 Available on Google Play: https://play.google.com/store/apps/details?id=com.boehringer.radiologyrounds&hl=en_US
News
News

Association of Abatacept with Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial
July 2025
CONCLUSION: Abatacept was associated with a lower risk of mortality compared with rituximab in patients with RA-ILD. Because clinicians may preferentially reserve abatacept for less aggressive RA-ILD, residual confounding by indication cannot be excluded; thus, the association should not be interpreted as proof of causality. Prospective randomized trials are needed to confirm whether abatacept confers a true survival advantage.

Classification and course of pulmonary hypertension associated with end-stage COPD
July 2025
CONCLUSION: Unbiased longitudinal invasive follow-up and assessment of lung volumes by plethysmography provided evidence of an association of lung volume and PVR.

High Prevalence of Abnormal Baseline Lung Function in Pediatric and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Report from the TRANSPIRE Study
July 2025
CONCLUSIONS: Pretransplant pulmonary dysfunction is common and predicts sustained posttransplant impairment and lower survival. Comprehensive baseline assessment may aid in risk stratification and guide early interventions to improve long-term respiratory outcomes in pediatric and young adult HSCT patients.

Lysophospholipid metabolism, clinical characteristics, and artificial intelligence-based quantitative assessments of chest CT in patients with stable COPD and healthy smokers
July 2025
The specific role of lysophospholipids (LysoPLs) in the pathogenesis of chronic obstructive pulmonary disease (COPD) is not yet fully understood. We determined serum LysoPLs in 20 patients with stable COPD and 20 healthy smokers using liquid chromatography-mass spectrometry (LC-MS) and matching with the lipidIMMS library, and integrated these data with spirometry, systemic inflammation markers, and quantitative chest CT generated by an automated 3D-U-Net artificial intelligence algorithm model....

Detection of structural pulmonary changes with real-time high-fidelity analysis of expiratory CO<sub>2</sub>
July 2025
There is an unmet need for breath-based markers for pulmonary vascular disease (PVD). We developed a fully-automatic algorithm to analyse expiratory CO2 flow from resting ventilation and evaluated the clinical associations of our readouts. 
We enrolled patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), pulmonary arterial hypertension (PAH) and healthy controls and evaluated fractionated volumes for dead space, mixed space (MSV) and alveolar space,...

Anti-Inflammatory Versus Antifibrotic Therapies for the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Protocol for a Systematic Review and Meta-Analysis
July 2025
CONCLUSIONS: This systematic review and meta-analysis will provide a comprehensive comparison of antifibrotic and anti-inflammatory therapies in the treatment of chronic RA-ILD. The findings will help inform clinical decision-making, support evidence-based treatment selection, and identify gaps in current research. By addressing both efficacy and safety, this review aims to guide future studies and improve patient outcomes for this complex and debilitating condition.

Treatment Strategies for Acute Exacerbation of Interstitial Lung Disease Associated with Systemic Autoimmune Rheumatic Diseases in Chinese Patients: A Scoping Review
July 2025
Connective tissue disease-related interstitial lung disease (CTD-ILD) refers to a range of pulmonary complications arising from connective tissue disorders, characterized by alveolar inflammation and interstitial fibrosis. Various factors, such as the specific type of connective tissue disease, infections, and hypoxemia, influence acute exacerbations of CTD-ILD. Treatment strategies typically include targeted interventions for precipitating factors, glucocorticoids, immunosuppressants, and...

Progressive Systemic Sclerosis-Associated Interstitial Lung Disease With Clinical-Radiographic Dissociation and Delayed Transplant Access: A Case Report
July 2025
Systemic sclerosis-associated interstitial lung disease (ILD) is a major contributor to morbidity and mortality in patients with diffuse systemic sclerosis. We present the case of a 47-year-old man with fibrotic non-specific interstitial pneumonia who experienced worsening hypoxemia and dyspnea following COVID-19, despite ongoing treatment with mycophenolate mofetil and prednisone. His oxygen requirement increased from 6-8 L/minute to 15 L/minute at rest, even as imaging showed stable fibrosis...

A potential new entity pending further validation of pulmonary primary interstitial Tumor: Lymphangioleiomyomatosis-like
July 2025
Primary pulmonary interstitial tumors represent a group of lung diseases. We encountered a case of a pulmonary primary interstitial tumor not previously reported in the literature. Based on existing research, this disease cannot be classified into any known subtype. We propose this disease as a potential new entity pending further validation-Pulmonary Primary Interstitial Tumor-Lymphangioleiomyomatosis-like (PIT-LAM). Histologically, this tumor is located within the interstitium, exhibiting...

Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab-sarotalocan sodium in a patient with oropharyngeal cancer: A case report
July 2025
CONCLUSION: We report the first case of DIILD caused by CS-PIT. Because cetuximab is a component of CS, CS-PIT has the potential to induce DIILD. Risk assessments and monitoring for DIILD are recommended for patients receiving CS-PIT.

Diagnostic yield and safety of transbronchial lung cryobiopsy using 1.7-mm probes in interstitial lung disease
July 2025
CONCLUSIONS: The incorporation of TBLC pathological findings in the MDD improved diagnostic certainty and facilitated decisions regarding treatment strategies. TBLC using a 1.7-mm single-use probe with a freezing duration of 5 s can safely obtain sufficient tissue specimens for the diagnosis of ILD.

Efficacy and safety of anlotinib combined with immunotherapy as first-line treatment in elderly patients with advanced non-small cell lung cancer
July 2025
CONCLUSIONS: Our findings suggest that the combination of anlotinib and immunotherapy represents a promising first-line therapeutic approach for elderly patients with locally advanced NSCLC, characterized by meaningful clinical efficacy and an acceptable safety profile. Further investigation may be warranted to validate the long-term therapeutic value of this treatment regimen in the elderly population.

Involvement of miR-205-5p in mediating the development of nodular thyroid disease associated with coal worker's pneumoconiosis via pulmonary extracellular vesicles
July 2025
CONCLUSION: miR-205-5p in pulmonary extracellular vesicles mediates the development of nodular thyroid disease associated with coal worker's pneumoconiosis through the ATF4/CHOP signaling axis. Further research is essential to comprehensively investigate the specific targets through which miR-205-5p derived from pulmonary extracellular vesicles triggers the development of nodular thyroid disease associated with coal worker's pneumoconiosis via the ATF4/CHOP signaling axis.

Exploration of pharmacodynamic material basis and mechanism of Jinbei Oral Liquid against idiopathic pulmonary fibrosis based on UHPLC-Q-TOF-MS/MS and network pharmacology
July 2025
This study aims to explore the pharmacodynamic material basis of Jinbei Oral Liquid(JBOL) against idiopathic pulmonary fibrosis(IPF) based on serum pharmacochemistry and network pharmacology. The ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry(UHPLC-Q-TOF-MS/MS) technology was employed to analyze and identify the components absorbed into rat blood after oral administration of JBOL. Combined with network pharmacology, the study explored the...

B cells and systemic sclerosis interstitial lung disease
July 2025
Interstitial lung disease is an important complication of systemic sclerosis (SSc-ILD) with high mortality and morbidity. Recent clinical studies in SSc-ILD have led to FDA-approved therapies in SSc-ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune rheumatic diseases. Pathogenesis of SSc-ILD involves interplay between fibroblasts and the innate and adaptive immune system. A central role for the B...

Circulating extracellular vesicles as predictive biomarkers of progressive interstitial lung disease in systemic sclerosis-a prospective cohort study
May 2025
CONCLUSION: Circulating EV levels are increased in SSc and correlate with ILD. In particular, ICAM1 + EVs may be a novel biomarker of PF-ILD, identifying SSc patients at high risk of progression who may require early aggressive treatment. Based on our results, the role of EVs in the pathogenesis and progression of ILD should be investigated further.

The Role of Anti-MDA5 Antibodies in Rapidly Progressive Interstitial Lung Disease: A Case Report and Literature Review
May 2025
CONCLUSION: This case underscores the need for increased awareness of this condition among clinicians to improve early diagnosis and treatment outcomes.

The Spectrum of Epidermolysis Bullosa in KwaZulu-Natal, South Africa
May 2025
CONCLUSION: JEB, with a recurrent pathogenic variant in LAMB3, emerged as the predominant subtype among African Zulu patients, underscoring the critical need for early diagnosis and tailored management strategies in resource-limited settings. Integrating clinicopathological and genetic data is essential for accurate diagnosis and prognosis, emphasizing the importance of advanced diagnostic tools in improving outcomes for EB patients in South Africa.

The Role of Bronchoscopy in the Diagnosis of Interstitial Lung Disease: A State-of-the-Art Review
May 2025
The diagnostic evaluation of interstitial lung diseases (ILDs) remains challenging due to their heterogeneous etiologies and overlapping clinical and radiographic patterns. A confident diagnosis often necessitates histopathological sampling, particularly when high-resolution computed tomography and serologic assessments are inconclusive. While surgical lung biopsy (SLB) has long been considered the diagnostic gold standard, its invasiveness, associated morbidity, and limited feasibility in...

Potential Utility of Combined Presepsin and LDH Tracking for Predicting Therapeutic Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Interstitial Lung Diseases: A Pilot Study
May 2025
Background/Objectives: The usefulness of presepsin, which is released from macrophages, in acute exacerbation of interstitial lung diseases (AE-ILDs) is unknown. We aimed to investigate the utility of monitoring presepsin with other AE-ILD markers before and after steroid pulse therapy in AE-ILDs. Methods: This pilot single-center retrospective observational study involved 16 patients with AE-ILDs, including the AE of idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial...
Testimonials
"The ILD Alliance of RhAPP & APAPP will provide our growing APP community with valuable resources to better educate and connect with ILD Experts based on your region."
"The ILD Alliance of RhAPP & APAPP will provide our growing APP community with valuable resources to better educate and connect with ILD Experts based on your region."
Amanda Mixon

"At the end of the day, it is all about our patients. Having a place where we can interact and learn from other ILD Experts in our community will only make our day-to-day patient care stronger and more effective."
"At the end of the day, it is all about our patients. Having a place where we can interact and learn from other ILD Experts in our community will only make our day-to-day patient care stronger and more effective."
Jessica Glennie

"Thanks to the ILD Alliance, I was able to connect with another APP in my region to discuss a few questions I had."
"Thanks to the ILD Alliance, I was able to connect with another APP in my region to discuss a few questions I had."
Daric Mueller

"I listened to the "Deep Dive Into ILD Therapeutics" podcast with Jessica Glennie and Cori Fratelli on my way to work. Podcasts like these help us understand what options we have to best treat our patients."
"I listened to the "Deep Dive Into ILD Therapeutics" podcast with Jessica Glennie and Cori Fratelli on my way to work. Podcasts like these help us understand what options we have to best treat our patients."
Felicia Mackey

"Being able to connect with other APPs in your region who are in different specialties is invaluable! I hope there are more alliances like these in the future."
"Being able to connect with other APPs in your region who are in different specialties is invaluable! I hope there are more alliances like these in the future."
Jeannette Hart
